CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Concordare Trials›
Library
Concordare Trials

Concordare Trials

Concordare Trials converts clinical study protocols into a digital model that generates source documents, EDC builds, and CTMS configurations.

HQ
New York, NY, US
Founded
2023
Loading
Overview
Compare
Employees
News
Library

Concordare Trials - Library

Official pages and third-party coverage in one index.

concordaretrials.org·36 items across 15 mapped pages · Crawled Sep 27, 2026·

Topics

Publication type

Content origin
Row density

Official pages and third-party coverage in one index

Product

7 pages
  1. Customers/customers

    Clinical teams in early access have shortened EDC setup and reduced post-enrollment amendments with Concordare. Explore pilot results and case studies.

  2. How It Works/how-it-works

    Upload a protocol PDF and receive an export-ready EDC build in four steps. See how Concordare parses, structures, and exports your study database.

  3. Integrations/integrations

    Export study designs to Medidata Rave, Oracle InForm, Veeva Vault EDC, Datatrak, and CTMS systems.

  4. Why Manual Transcription Dominates Protocol Setup Time/journal/why-manual-transcription-dominates-protocol-setup-time

    In the first weeks of a study build, a clinical data manager reads the protocol, extracts requirements, and manually recreates them in an EDC.

Blog

6 pages
  1. Building a Study Ready Database Protocol to Crf/journal/building-a-study-ready-database-protocol-to-crf

    A study-ready clinical trial database translates protocol visits, endpoints, eligibility criteria, and collection requirements into traceable EDC forms, variables, and edit checks.

  2. Ctms Integration Patterns for Decentralized Studies/journal/ctms-integration-patterns-for-decentralized-studies

    Decentralized studies distribute complexity across systems. A coherent CTMS build depends on deliberate integration architecture, shared identifiers, and defined status logic.

  3. Edc Setup Time the Cost of Manual Protocol Transcription/journal/edc-setup-time-the-cost-of-manual-protocol-transcription

    EDC licensing is easy to budget, but the labor of reading a protocol and rebuilding it manually in a study database often remains hidden.

  4. Etmf Integration for Modern Study Builds/journal/etmf-integration-for-modern-study-builds

    The eTMF and EDC evolve together, but disconnected build workflows can leave approved protocol versions and database logic out of alignment.

Press

1 page
  1. Media/media

    Product updates, industry insights and company news from Concordare Trials on digital protocols, site operations and clinical trial data quality.

Careers & Hiring

1 page
  1. Careers/careers

    Open roles at Concordare Trials. Help build the digital clinical trial protocol that hospitals and sponsors use to launch and run studies faster.

Pricing

2 pages
  1. Platform/platform

    Concordare's protocol intelligence platform reads clinical trial PDFs and creates study-ready EDC database builds. Parse, generate, and export in one workflow.

  2. Pricing/pricing

    Concordare Trials pricing for clinical teams, with Build, Team, and Enterprise tiers for protocol digitization and EDC builds.

About

2 pages
  1. About/about

    Concordare Trials is a Cambridge clinical technology company creating automated protocol-to-EDC build software for clinical data management teams.

  2. About/about

    Concordare Trials is building the digital clinical trial protocol. Meet the team, advisors and partners behind the Clinical Trial Protocol Model.

Contact

5 pages
  1. Contact/contact

    Contact Concordare Trials about early access or technical support. General inquiries receive a reply within 1 business day.

  2. Contact/contact

    Get in touch with Concordare Trials. Talk to sales about a demo or pricing, reach product support, or send a general inquiry.

  3. General/contact/general

    Send Concordare Trials a question, partnership inquiry or anything else that is not a sales or support request.

  4. Sales/contact/sales

    Talk to the Concordare Trials sales team about a demo, pricing or rollout for your research site, CRO or sponsor.

Homepage

2 pages
  1. Homepage/

    Concordare converts a clinical trial protocol PDF into a structured EDC build in 48 hours. Start studies weeks sooner with fewer later amendments.

  2. Homepage/

    The first fully digital clinical trial protocol, helping hospitals and pharmaceutical sponsors launch and run studies faster with higher-quality data.

Privacy

1 page
  1. Privacy/privacy

    Privacy Policy for Concordare Trials.

Terms & Conditions

1 page
  1. Terms/terms

    Terms of Service for Concordare Trials.

Not yet classified

2 pages
  1. concordaretrials.org/

    Concordare converts a clinical trial protocol PDF into a structured EDC build in 48 hours. Start studies weeks sooner with fewer later amendments.

  2. concordaretrials.com/

    The first fully digital clinical trial protocol, helping hospitals and pharmaceutical sponsors launch and run studies faster with higher-quality data.

Coverage

6 items
  1. Concordare Trials Raises Funding to Digitize Clinical Protocolsdigitalhealthfunding.com/concordare-trials-raises-funding-to-digitize-clinical-trial-protocols/

    Concordare Trials, founded by CEO Zach Sawaged, raises funding to digitize clinical protocols after Sawaged spends a decade working across clinical research sites, sponsors, and technology vendors. Surface Ventures leads the investment round, joined by Techstars, Innovation Works, Gaingels, and individual investors.

    Aug 2026 · Digital Health FundingNews article

  2. Concordare Trials Secures Funding Round to Accelerate Digitization of Clinical Trial Protocolssignalnewsphiladelphia.com/press-releases/62480/concordare-trials-secures-funding-round-to-accelerate-digitization-of-clinical-trial-protocols/

    Concordare Trials secures a funding round led by Surface Ventures, with participation from Techstars, Innovation Works, Gaingels, and individual investors. It converts static clinical trial protocol PDFs into a structured, interoperable digital format that every downstream system can use.

    Aug 2026 · Business Wire via SignalNewsNews article

  3. The Galien Foundation Announces 2026 Prix Galien USA Nominees including Best Startupprnewswire.com/news-releases/the-galien-foundation-announces-2026-prix-galien-usa-nominees-for-best-digital-health-solution-best-medical-technology-incubators-accelerators-and-equity-and-best-startup-302850770.html

    The Galien Foundation announces its 2026 Prix Galien USA award nominees, with Concordare Trials listed in the Best Startup category among the nominees. The awards ceremony is scheduled for October 29, 2026, in New York City.

    Aug 2026 · PR Newswire / NasdaqNews article

  4. Meet the Startups Joining Techstars Spring 2026 Accelerator Programstechstars.com/newsroom/meet-the-startups-joining-techstars-spring-2026-accelerator-programs

    Techstars introduces its Spring 2026 accelerator class, which includes Obert in the Workforce Development Accelerator. Obert is a workwear brand addressing women's safety in male-dominated fields.

    Mar 2026 · TechstarsNews article